Halozyme Announces Change In Primary Endpoint For HALO-301 To Overall Survival

Author's Avatar
Nov 27, 2018
Article's Main Image

-FDA Agrees to Company Request to Change Primary Endpoint to Overall Survival-

-Previously Planned Interim Analysis Will Not Be Conducted-

-Management to Host Webcast / Conference Call Today at 5 p.m. ET / 2 p.m. PT-

PR Newswire